 |
|
|
| |
ABT-493, a Potent HCV NS3/4A Protease Inhibitor With Broad Genotype Coverage
|
| |
| |
Reported by Jules Levin
CROI 2014 Boston, MA March 3-6
Teresa Ng1, Thomas Reisch1, Tim Middleton1, Keith McDaniel1, Dale Kempf1, Liangjun Lu1, Guoqiang Wang2, Lijuan Jiang2, Yat Sun Or2, Tami Pilot-Matias1
1AbbVie Inc., North Chicago, Illinois, United States; 2Enanta Pharmaceuticals Inc., Watertown, Massachusetts, United States
|
| |
|
|
|
|
|
